Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nebion recall

This article was originally published in The Gray Sheet

Executive Summary

FDA recalls Nebion's HLX-8 magnetic resonance device, which the company claimed can treat medical conditions such as cancer, carpel tunnel syndrome, migraines, arthritis and certain injuries, but is not FDA approved. Nebion "failed to provide FDA with any evidence to support these claims," FDA writes in an Oct. 3 Class I recall notice. On July 2, Nebion notified customers about the recall and instructed them to stop using the device and to report any adverse reactions or problems to FDA

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel